NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as ON TARGET LABS. It is marketed under 1 brand name, including CYTALUX. Available in 1 different strength, such as EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML), and administered through 1 route including SOLUTION;INTRAVENOUS.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"73449","ingredient":"PAFOLACIANINE SODIUM","trade_name":"CYTALUX","family_id":"a35098b6ba54447b9f47","publication_number":"US10881747B2","cleaned_patent_number":"10881747","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-08-26","publication_date":"2021-01-05","legal_status":"Patented case"} | US10881747B2 Molecular Formulation | 05 Jan, 2021 | Patented case | 26 Aug, 2033 | |
| {"application_id":"73443","ingredient":"PAFOLACIANINE SODIUM","trade_name":"CYTALUX","family_id":"a35098b6ba54447b9f47","publication_number":"US9061057B2","cleaned_patent_number":"9061057","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-08-26","publication_date":"2015-06-23","legal_status":"Granted"} | US9061057B2 Molecular Formulation | 23 Jun, 2015 | Granted | 26 Aug, 2033 | |
| {"application_id":"73414","ingredient":"PAFOLACIANINE SODIUM","trade_name":"CYTALUX","family_id":"a35098b6ba54447b9f47","publication_number":"US9333270B2","cleaned_patent_number":"9333270","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-08-26","publication_date":"2016-05-10","legal_status":"Granted"} | US9333270B2 Molecular Formulation | 10 May, 2016 | Granted | 26 Aug, 2033 | |
| {"application_id":"73446","ingredient":"PAFOLACIANINE SODIUM","trade_name":"CYTALUX","family_id":"a35098b6ba54447b9f47","publication_number":"US9341629B2","cleaned_patent_number":"9341629","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-08-26","publication_date":"2016-05-17","legal_status":"Patented case"} | US9341629B2 Molecular Formulation | 17 May, 2016 | Patented case | 26 Aug, 2033 | |
| {"application_id":"73448","ingredient":"PAFOLACIANINE SODIUM","trade_name":"CYTALUX","family_id":"a35098b6ba54447b9f47","publication_number":"US9789208B2","cleaned_patent_number":"9789208","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-08-26","publication_date":"2017-10-17","legal_status":"Granted"} | US9789208B2 Molecular Formulation | 17 Oct, 2017 | Granted | 26 Aug, 2033 | |
| {"application_id":"73445","ingredient":"PAFOLACIANINE SODIUM","trade_name":"CYTALUX","family_id":"a35098b6ba54447b9f47","publication_number":"US9254341B2","cleaned_patent_number":"9254341","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-10-04","publication_date":"2016-02-09","legal_status":"Granted"} | US9254341B2 Molecular Formulation | 09 Feb, 2016 | Granted | 04 Oct, 2033 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Pafolacianine Sodium
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.